Table 2.
Analysis of pharmacokinetics (PK) and pharmacodynamics (PD); morning trough values of 10 HTx recipients suffering from severe renal dysfunction, before and after treatment change from cyclosporin to sirolimus
| Cyclosporin | Sirolimus | ||||
|---|---|---|---|---|---|
| Day 0 | Day 1 | Day 2 | Day 3 | Day 4 | |
| PK | (ng/ml) | (µg/ml) | |||
| 98.0 | 0.0 | 9.0 | 9.8 | 9.3 | |
| PD | (% expression) | (% expression) | |||
| PCNA | 4.5 | 4.2 | 5.8 | 6.4 | 4.0 |
| CD25 | 12.4 | 13.1 | 13.4 | 15.7 | 19.4 |
| CD95 | 8.3 | 8.1 | 9.2 | 9.8 | 15.3 |
| CD134 | 8.0 | 7.0 | 8.2 | 7.1 | 12.3 |
| INF‐γ | 28.0 | 25.4 | 12.3 | 19.2 | 12.7 |
| TNF‐α | 16.4 | 15.8 | 13.6 | 14.5 | 13.5 |
| IL‐2 | 13.3 | 13.0 | 7.6 | 10.3 | 9.3 |
| IL‐4 | 5.7 | 5.6 | 7.6 | 5.5 | 6.4 |